Multiple Sclerosis, Relapsing-RemittingPhase 2INCREASENCT03387046
A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)
A Phase 2 study testing D-aspartate, IFN beta-1a and Methylprednisolone in people with Multiple Sclerosis, Relapsing-Remitting, run by Merck KGaA, Darmstadt, Germany at 17 sites in Italy.
Trial summary
The purpose of this study was to evaluate the improvement in spontaneous recovery from clinical deficits at the time of an acute relapse in RR-MS participants already receiving interferon (IFN) beta 1a with D-aspartate (versus placebo) as add-on therapy. Read more about this study
- Who is it for?
- Ages 18 to 55 years
- Conditions the study is for
- Multiple Sclerosis, Relapsing-Remitting
- What is being tested?
- D-aspartate, IFN beta-1a and Methylprednisolone
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 7 participants
- Where
- 17 sitesItaly
- Study dates
- 26 Mar 2018to 11 Jan 2019
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Participants with RR-MS, according to the revised McDonald Criteria (2010)
- Participants with an expanded disability status scale (EDSS) score between 0 and 3 before screening visit and before relapse
- Participants receiving treatment with IFN beta 1a 44 mcg three times a week for at least 6 months but for no more than 10 years before the screening visit
- Female participants must be neither pregnant nor breastfeeding and must lack childbearing potential
- Participants willing and able to comply with the protocol for the total duration of the study
- Participants able to understand the purposes and the risks of the study
Show all 11Show fewer
- Participants have signed the appropriate written informed consent form, approved by the Independent Ethics Committee (IEC), prior to the performance of any study activities
- For MS participants with relapse:
- Deterioration of at least one step in a relevant Functional Systems Scale (FSS) or an increase in EDSS of 1 point or more compatible, according to physician's judgment, with the therapy prosecution
- Relapse started within maximum 5 days before the inclusion in the study
- MS participants without relapse with clinically stable RR-MS
Who cannot join
- Participants with diagnosis of primary progressive MS (PP-MS)
- Participants have any disease other than MS that could better explain his/her signs and symptoms
- Participants with any comorbidity with diseases that might alter synaptic plasticity (example Parkinson Disease, Alzheimer Disease, Stroke)
- Participants receiving concomitant treatment with drugs that may alter synaptic plasticity (example, cannabinoids)
- Participants with history or presence of any unstable medical condition (tumor or chronic infection or severe life threatening infection within the last 6 months)
- Participants who have received any corticosteroids therapy within 3 months prior to the screening
Show all 20Show fewer
- Participants with any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressive agents during the course of the study
- Participants who have received any immunosuppressive agents other to corticosteroids, as monotherapy or combination therapy within 3 months prior to the screening visit
- Participants with history or currently active primary or secondary immunodeficiency
- Participants with inadequate liver function, defined by alanine aminotransferase (ALT) > 3 * upper limit of normal (ULN), or alkaline phosphatase (AP) > 2 * ULN, or total bilirubin > 2 * ULN if associated with any elevation of ALT or AP
- Participants with inadequate bone marrow reserve, defined as a white blood cell count less than 0.5 * lower limit of normal (LLN)
- Participants with moderate to severe renal impairment
- Participants unable to complete an magnetic resonance imaging (MRI) (contraindications for MRI include but are not restricted to weight >=140 kilogram (kg), pacemaker, cochlear implants, presence of foreign substances in the eye, intracranial vascular clips, surgery within 6 weeks of entry into the study, coronary stent implanted within 8 weeks prior to the time of the intended MRI, etc)
- Participants with contraindication to gadolinium (Gd) can be enrolled into the study but cannot receive Gd contrast dyes during their MRI scans
- Participants receiving supplements that, in the Investigator's opinion, may affect the evaluation of fatigue
- Participants with any known contraindications or hypersensitivity to D-aspartate or any excipient
- Participants with any other significant disease that in the Investigator's opinion would impede study assessments or endanger the participant
- Female participants with positive pregnancy test at baseline or participants with active project of pregnancy during the study
- Participants with legal incapacity or limited legal capacity
- Participants have participated in any other investigational study within 8 weeks before the screening visit
Trial locations and contacts
17 sites in 1 country.
17 sites in 1 country
Italy17 sites
Ospedale Binaghi, Università di Cagliari,ASL 8
Cagliari
Ospedale Clinicizzato SS. Annunziata
Chieti
Azienda Socio Sanitaria Territoriale della Valle Olona (presidio di Gallarate)
Gallarate
Azienda Ospedaliero Universitaria San Martino
Genova
Ospedale P.A.Micone
Genova
Ospedale San Raffaele
Milan
A.O.U. Federico II
Naples
Azienda Ospedaliera di Rilievo Nazionale A. CardarelliAzienda Ospedaliera di Rilievo Nazionale A. Cardarelli
Naples
Seconda Università degli Studi di Napoli
Naples
Azienda Ospedaliera di Padova
Padova
I.R.C.C.S. Neuromed-Istituto Neurologico Mediterraneo
Pozzilli
Azienda Ospedaliera San Camillo Forlanini
Roma
Azienda Ospedaliera Sant'Andrea-Università di Roma La Sapienza
Roma
Policlinico Universitario Agostino Gemelli
Roma
Azienda Ospedaliera Universitaria Policlinico Tor Vergata
Rome
Ospedale S. Paolo
Savona
Azienda Ospedaliero Universitaria Ospedali Riuniti
Torrette Di Ancona
About this study
Official title: Evaluation of clINical reCovery After a Relapse: a Pilot Study assEssing the Neuronal Effects of D-Aspartate in RR-MS Subjects Treated With IntErferon Beta 1a 44 mcg TIW (INCREASE)
The purpose of this study was to evaluate the improvement in spontaneous recovery from clinical deficits at the time of an acute relapse in RR-MS participants already receiving interferon (IFN) beta 1a with D-aspartate (versus placebo) as add-on therapy.
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Being tested
- D-aspartate, Placebo, IFN beta-1a, Methylprednisolone
- Keywords
- Relapsing remitting multiple sclerosis, D-Aspartate, interferon beta-1a
- Medical subject headings
- Multiple Sclerosis, Relapsing-Remitting
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
D-aspartateDietary supplement
D-aspartate 2660 milligram (mg) once daily in the form of oral solution for 24 weeks.
PlaceboDrug
Placebo matched to D-aspartate once daily in the form of oral solution for 24 weeks.
IFN beta-1aBiological
IFN beta-1a was administered subcutaneously at a dose of 44 microgram (mcg) three times a week for 24 weeks.
Methylprednisolone 1000 mg was administered intravenously once daily for 5 consecutive days.
| Study group | Role | What they receive |
|---|---|---|
| D-aspartate + IFN beta-1a + Methylprednisolone | Experimental | Participants received D-aspartate 2660 milligrams (mg) once daily in the form of oral solution for 24 weeks along with IFN beta-1a subcutaneously (sc) at a dose of 44 microgram (mcg) three times a week (TIW) in participants without relapse and IFN beta-1a sc TIW plus Methylprednisolone 1000 mg intravenously once daily for 5 consecutive days in participants with relapse. Receives: Dietary Supplement: D-aspartate; Biological: IFN beta-1a; Drug: Methylprednisolone |
| Placebo + IFN beta-1a + Methylprednisolone | Placebo comparator | Participants received placebo matched to D-aspartate once daily in the form of oral solution for 24 weeks along with IFN beta-1a subcutaneously (sc) at a dose of 44 microgram (mcg) three times a week (TIW) in participants without relapse and IFN beta-1a sc TIW plus Methylprednisolone 1000 mg intravenously once daily for 5 consecutive days in participants with relapse. Receives: Drug: Placebo; Biological: IFN beta-1a; Drug: Methylprednisolone |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 8
EDSS is an ordinal scale in half-point increments that qualifies disability in participants with Multiple Sclerosis (MS). It assesses the 8 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder, cerebral and other) as well as ambulation. EDSS overall score ranging from 0 (normal) to 10 (death due to MS).
Measured: Baseline, Week 8
Secondary outcomes (9)
Number of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 12 and 24
EDSS is an ordinal scale in half-point increments that qualifies disability in participants with Multiple Sclerosis. It assesses the 8 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder, cerebral and other) as well as ambulation. EDSS overall score ranging from 0 (normal) to 10 (death due to MS).
Measured: Baseline, Week 12 and 24
25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
The Timed 25-Foot Walk is a quantitative measure of lower extremity function. The participants is directed to one end of a clearly marked 25-foot (7.62 m) course and is instructed to walk 25 feet (7.62 meter) as quickly as possible, but safely. The task is immediately administered again by having the participant walk back the same distance. Participants may use assistive devices when doing this task. The test scores were the time in seconds it took to walk the 25 feet. The data for the 25-FWT is reported for the 2 completed trials. Participant wise data was reported for this outcome.
Measured: At Week 8, 12 and 24
9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The data for the 29HPT is reported for the 2 completed trials. Participant wise data was reported for this outcome.
Measured: Week 8, 12 and 24
Symbol Digit Modalities Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
Symbol digit modalities test is to evaluate neurocognitive functions. This measure involves a coding key consisting of 9 abstract symbols, each paired with a number ranging from 1 to 9. The participants is required to scan the key and write down the number corresponding to each symbol as fast as possible. The number of correct substitution within 90 seconds is recorded. In the written version of the test the participants fills in the numbers that correspond to the symbols. The score is the number of correctly coded items from 0-110 in 90 seconds. A higher score indicates better performance. Participant wise data was reported for this outcome.
Measured: At Week 8, 12 and 24
Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
Visual acuity is measured under low contrast conditions (10% contrast relative to the chart background) at object testing distances of 10 feets and is reported as the number of letters read correctly (ranging from 0 to 10 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates that vision has improved. Participant wise data was reported for this outcome.
Measured: Week 8, 12 and 24
Modified Fatigue Impact Scale (MFIS) Score to Measure Fatigue at Week 8, 12 and 24
MFIS is a structured, self-report questionnaire consisting of 21 items assessing the effects of fatigue. All 21 items are scaled 0 to 4, with higher scores indicating a greater impact of fatigue on participant's activities. The Total MFIS score ranges from 0 to 84. A score of 0 indicates fatigue has no impact on activities and the high-end score indicates fatigue has extreme impact on activities. Participant wise data was reported for this outcome.
Measured: Week 8, 12 and 24
Fatigue Severity Scale (FSS) Score to Measure Fatigue by at Week 8, 12 and 24
Fatigue Severity Scale (FSS) is a method of evaluating fatigue in multiple sclerosis and is designed to differentiate fatigue from clinical depression, since both share some of the same symptoms. The Fatigue Severity Scale is a 9-item questionnaire developed to assess the level of fatigue due to neurological disease, were each assessed on a 1-7 scale (1= no fatigue and 7= severe fatigue). The total score was calculated as the average of individual 9-items and ranged from 1 to 7 with a higher value indicating greater impairment due to fatigue. Participant wise data was reported for this outcome.
Measured: Week 8, 12 and 24
Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS)
TMS is an electrophysiological technique that was used to measure neurologic changes associated with recovery from stroke via alterations in the excitability of the motor system. Motor threshold measures reflect global excitability of the corticospinal pathway, including large pyramidal cells, excitatory/inhibitory interneurons, and spinal motor neurons. Long term potentiation can be measured non invasively and painlessly, in awake humans through transcranial magnetic stimulation (TMS). TMS uses high intensity, brief duration, magnetic fields that, when applied on the scalp, can activate neurons within a small focal region of the cerebral cortex, through electromagnetic induction. Motor Evoked Potentials (MEP) amplitudes elicited by single TMS pulses of increasing intensity (110, 120 and 130% of the Resting Motor Threshold [RMT]) will be measured to calculate recruitment curves of the motor cortex. Participant wise data was reported for this outcome.
Measured: Baseline (0 minute) and Post-Baseline (15 minutes) at Week 8
Number of Treated Participants With Immune-metabolic Response of Lymphocytes
Treated participants with immune-metabolic response (glycolysis, mitochondrial respiration, fatty acids oxidation and circulating adipocytokines) of lymphocytes were to be reported.
Measured: Baseline, Week 8 and 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Dec 2017
- Study start26 Mar 2018
- Primary completion11 Jan 2019
- Study completion11 Jan 2019
Why it stopped: Study was terminated early due to slow recruitment rate.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Multiple Sclerosis, Relapsing-RemittingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 7 participants (actual)
Sponsor and investigators
- Lead sponsor
- Merck KGaA, Darmstadt, Germany
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Medical Responsible, Study director, Merck KGaA, Darmstadt, Germany
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03387046
- Sponsor's protocol ID
- MS200136_0041
- Acronym
- INCREASE
- Status last verified
- Feb 2020
- First submitted
- 22 Dec 2017
- Last updated
- 10 Feb 2020
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Feb 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of clINical reCovery After a Relapse: a Pilot Study assEssing the Neuronal Effects of D-Aspartate in RR-MS Subjects Treated With IntErferon Beta 1a 44 mcg TIW (INCREASE)
- ClinicalTrials.gov ID
- NCT03387046
- Acronym / sponsor ID
- INCREASE / MS200136_0041
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Keywords
- Relapsing remitting multiple sclerosis, D-Aspartate, interferon beta-1a
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Study was terminated early due to slow recruitment rate.
- Enrolment
- 7 participants (actual)
- Lead sponsor
- Merck KGaA, Darmstadt, GermanyIndustry (pharma, biotech, devices)
- Study start
- 26 Mar 2018 (actual)
- Primary completion
- 11 Jan 2019 (actual)
- Study completion
- 11 Jan 2019 (actual)
- First posted
- 29 Dec 2017 (actual)
- Results
- Posted 10 Feb 2020
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study was to evaluate the improvement in spontaneous recovery from clinical deficits at the time of an acute relapse in RR-MS participants already receiving interferon (IFN) beta 1a with D-aspartate (versus placebo) as add-on therapy.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| D-aspartate + IFN beta-1a + Methylprednisolone | Experimental | Dietary Supplement: D-aspartate, Biological: IFN beta-1a, Drug: MethylprednisoloneParticipants received D-aspartate 2660 milligrams (mg) once daily in the form of oral solution for 24 weeks along with IFN beta-1a subcutaneously (sc) at a dose of 44 microgram (mcg) three times a week (TIW) in participants without relapse and IFN beta-1a sc TIW plus Methylprednisolone 1000 mg intravenously once daily for 5 consecutive days in participants with relapse. |
| Placebo + IFN beta-1a + Methylprednisolone | Placebo comparator | Drug: Placebo, Biological: IFN beta-1a, Drug: MethylprednisoloneParticipants received placebo matched to D-aspartate once daily in the form of oral solution for 24 weeks along with IFN beta-1a subcutaneously (sc) at a dose of 44 microgram (mcg) three times a week (TIW) in participants without relapse and IFN beta-1a sc TIW plus Methylprednisolone 1000 mg intravenously once daily for 5 consecutive days in participants with relapse. |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (11 listed)
- Participants with RR-MS, according to the revised McDonald Criteria (2010)
- Participants with an expanded disability status scale (EDSS) score between 0 and 3 before screening visit and before relapse
- Participants receiving treatment with IFN beta 1a 44 mcg three times a week for at least 6 months but for no more than 10 years before the screening visit
- Female participants must be neither pregnant nor breastfeeding and must lack childbearing potential
- Participants willing and able to comply with the protocol for the total duration of the study
Key exclusion criteria (20 listed)
- Participants with diagnosis of primary progressive MS (PP-MS)
- Participants have any disease other than MS that could better explain his/her signs and symptoms
- Participants with any comorbidity with diseases that might alter synaptic plasticity (example Parkinson Disease, Alzheimer Disease, Stroke)
- Participants receiving concomitant treatment with drugs that may alter synaptic plasticity (example, cannabinoids)
- Participants with history or presence of any unstable medical condition (tumor or chronic infection or severe life threatening infection within the last 6 months)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| D-aspartateD-aspartate 2660 milligram (mg) once daily in the form of oral solution for 24 weeks. | Dietary supplement | D-aspartate + IFN beta-1a + Methylprednisolone |
| PlaceboPlacebo matched to D-aspartate once daily in the form of oral solution for 24 weeks. | Drug | Placebo + IFN beta-1a + Methylprednisolone |
| IFN beta-1aIFN beta-1a was administered subcutaneously at a dose of 44 microgram (mcg) three times a week for 24 weeks. | Biological | D-aspartate + IFN beta-1a + Methylprednisolone, Placebo + IFN beta-1a + Methylprednisolone |
| MethylprednisoloneMethylprednisolone 1000 mg was administered intravenously once daily for 5 consecutive days. | Drug | D-aspartate + IFN beta-1a + Methylprednisolone, Placebo + IFN beta-1a + Methylprednisolone |
Primary outcome
Number of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 8
Time frame: Baseline, Week 8
EDSS is an ordinal scale in half-point increments that qualifies disability in participants with Multiple Sclerosis (MS). It assesses the 8 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder, cerebral and other) as well as ambulation. EDSS overall score ranging from 0 (normal) to 10 (death due to MS).
9 secondary outcomes
Number of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 12 and 24
Time frame: Baseline, Week 12 and 24
25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
Time frame: At Week 8, 12 and 24
9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
Time frame: Week 8, 12 and 24
Symbol Digit Modalities Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
Time frame: At Week 8, 12 and 24
Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
Time frame: Week 8, 12 and 24
Modified Fatigue Impact Scale (MFIS) Score to Measure Fatigue at Week 8, 12 and 24
Time frame: Week 8, 12 and 24
Fatigue Severity Scale (FSS) Score to Measure Fatigue by at Week 8, 12 and 24
Time frame: Week 8, 12 and 24
Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS)
Time frame: Baseline (0 minute) and Post-Baseline (15 minutes) at Week 8
Number of Treated Participants With Immune-metabolic Response of Lymphocytes
Time frame: Baseline, Week 8 and 12
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Feb 2020.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Multiple Sclerosis, Relapsing-Remitting
RecruitingObservational study
Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
RecruitingObservational study
REAL-MS: Observational Database Study of AHSCT and MS Therapies
Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
Active, not recruiting
Tai Chi Training for Persons With Multiple Sclerosis.
Multiple Sclerosis (MS) - Relapsing-remitting
RecruitingPhase 2
The HIt HArd and hiT Early in Multiple Sclerosis Trial
Relapsing-remitting Multiple Sclerosis
RecruitingPhase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Medical Responsible study director
Merck KGaA, Darmstadt, Germany
17 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing D-aspartate, IFN beta-1a and Methylprednisolone in people with Multiple Sclerosis, Relapsing-Remitting, run by Merck KGaA, Darmstadt, Germany at 17 sites in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 10 Feb 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 17 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 10 Feb 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 8 (time frame: Baseline, Week 8). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Feb 2020.